By inhibiting plasmin, TFPI-2 effectively decreases activation of MMP-1, MMP-3 and MMP-9 (Rao et al, 1999), and reduces the invasive potential of several tumour cell lines including A549, an NSCLC cell line (Lakka et al, 2000). This evidence concerns the gene TFPI2 and non-small cell lung carcinoma.